MALT1 and cholangiocarcinoma: To confirm that MALT1 is also a therapeutic target of CCA, we showed that MALT1-knockdown HuCCT1 cells are more sensitive to regorafenib (Figure 2B) and MI-2 inhibits the proliferation of CCA cell lines (Figure 2C).